Eye medicine spending to top 23 billion by 2020
Ophthalmic drugs remain the preferred approach to treat common eye disorders, from dry eye syndrome to glaucoma and AMD, forecast suggests
19 July 2017
A report predicting trends in the ophthalmic drugs market suggests the global market for medicine to treat eye disease will surpass £23 bn by 2020.
A summary of The Ophthalmic Drugs Market: 2017–2030, published by SNS research, states that although surgery is the only option for the treatment of some eye conditions, including cataracts, ophthalmic drugs continue to account for the highest percentage of spending within the wider market for ophthalmic products.
“As a higher percentage of the global population lives longer, age related eye disorders such as glaucoma, diabetic retinopathy, cataracts and macular degeneration are on the rise,” the summary explains.
“In addition, a host of modern lifestyle habits such as poor eating, overworking and the excessive use of visual displays, have created an environment rife with conditions such as dry eye syndrome and myopia.”
The report summary states that new research and development programmes are primarily focused on anti-inflammatory agents, long-acting anti-VEGF treatments, rho kinase inhibitors, adenosine agonists, nitric oxide donors, combination therapies, complement factor inhibitors and cell therapies, among other areas.
Drug developers are also investing in the development of convenient and potentially cost-effective delivery routes, including oral delivery, intravitreal implants and dissolvable intracanalicular depots.